

# ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity

Jared M. Odegard,<sup>1</sup> Benjamin R. Marks,<sup>1</sup> Leah D. DiPlacido,<sup>1</sup> Amanda C. Poholek,<sup>2</sup> Dwight H. Kono,<sup>5</sup> Chen Dong,<sup>1</sup> Richard A. Flavell,<sup>1,3</sup> and Joe Craft<sup>1,4</sup>

<sup>1</sup>Department of Immunobiology, <sup>2</sup>Department of Cell Biology, <sup>3</sup>Howard Hughes Medical Institute, and <sup>4</sup>Section of Rheumatology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520  
<sup>5</sup>Department of Immunology and Microbial Sciences, Scripps Research Institute, La Jolla, CA 92037

**The role of specialized follicular helper T ( $T_{FH}$ ) cells in the germinal center has become well recognized, but it is less clear how effector T cells govern the extrafollicular response, the dominant pathway of high-affinity, isotype-switched autoantibody production in the MRL/MpJ-*Fas*<sup>pr</sup> (MRL<sup>pr</sup>) mouse model of lupus. MRL<sup>pr</sup> mice lacking the *ICOS* gene have impaired extrafollicular differentiation of immunoglobulin (Ig) G<sup>+</sup> plasma cells accompanied by defects in CXC chemokine receptor (CXCR) 4 expression, interleukin (IL) 21 secretion, and B cell helper function in CD4 T cells. These phenotypes reflect the selective loss of a population of T cells marked by down-regulation of P-selectin glycoprotein ligand 1 (PSGL-1; also known as CD162). PSGL-1<sup>lo</sup> T cells from MRL<sup>pr</sup> mice express CXCR4, localize to extrafollicular sites, and uniquely mediate IgG production through IL-21 and CD40L. In other autoimmune strains, PSGL-1<sup>lo</sup> T cells are also abundant but may exhibit either a follicular or extrafollicular phenotype. Our findings define an anatomically distinct extrafollicular population of cells that regulates plasma cell differentiation in chronic autoimmunity, indicating that specialized humoral effector T cells akin to  $T_{FH}$  cells can occur outside the follicle.**

---

**CORRESPONDENCE**  
 Joe Craft:  
 joseph.craft@yale.edu

Abbreviations used: AFC, antibody-forming cell; AID, activation-induced cytidine deaminase; CGG, chicken  $\gamma$  globulin; CSR, class switch recombination; GC, germinal center; ICOS, inducible T cell co-stimulator; MRL<sup>pr</sup>, MRL/MpJ-*Fas*<sup>pr</sup>; NP, nitrophenyl; NZB/W F1, (NZB/BINJ  $\times$  NZW/LacJ) F1; P-lig, P-selectin ligand; PSGL-1, P-selectin glycoprotein ligand 1; RIP-LT $\alpha$  $\beta$ , rat insulin promoter-driven lymphotoxin  $\alpha$  and  $\beta$ ;  $T_{FH}$  cell, follicular helper T.

CD4 T cells control several aspects of immune responses, and there is growing recognition that individual Th functions are mediated by distinct subsets. This paradigm is particularly clear for the peripheral tissue effector lineages Th1, Th2, and Th17, which each control a distinct class of innate immune mediators (1). These inflammatory effectors can be distinguished from T cells that perform the other essential and historically emblematic Th function, the regulation of antibody responses. However, our insight into the nature of such humoral effectors is relatively limited. The classical model that Th2 cells are responsible for antibody production (2) has been criticized for failing to ac-

count for the production of the Th1-associated isotypes IgG2a and IgG2b (3). Further, although mice that lack the IL-4R signaling molecule STAT6 have severe defects in peripheral Th2 responses, they produce normal levels of the IgG isotypes upon immunization (4), indicating that Th2 development is dispensable even for IgG1 production.

More recently, consideration of the anatomy of antibody responses has provided insights into the specialized nature of B Th cells, although a comprehensive description of such CD4 Th subsets, which we refer to generally as humoral effectors, has yet to be achieved. The initial interactions between antigen-engaged CD4 T cells and B cells occur at the border of the T cell zone and follicle (5), and the early effects

---

B.R. Marks and L.D. DiPlacido contributed equally to this paper.

J.M. Odegard's present address is Dept. of Immunology, University of Washington, Seattle, WA 98195.

C. Dong's present address is Dept. of Immunology, M.D. Anderson Cancer Center, Houston, TX 77030.

The online version of this article contains supplemental material.

---

© 2008 Odegard et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.jem.org/misc/terms.shtml>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

of Th cytokines can be observed there with the appearance of Ig heavy chain germline transcripts, the precursors to class switch recombination (CSR) (6, 7). Subsequently, subsets of B cells and Th cells migrate to the follicle and ultimately form the germinal center (GC), from which high-affinity, class-switched, and long-lived plasma cells and memory B cells emerge (5). Localization of T cells around the GC light zone as well as an ongoing CD40L requirement for affinity maturation in the GC indicate that selection of mutant B cells is a critical function of T cell help at that site (8, 9). More recent work has provided the significant insight that this T cell function is mediated by a distinct follicular helper T (T<sub>FH</sub>) cell subset (10–12).

Characterization of the follicle-resident T<sub>FH</sub> cell subset in human tonsil has been facilitated by the identification of the surface markers CXCR5 and CD57 (12). More recently, T<sub>FH</sub> cell differentiation has been achieved in vitro, allowing their further characterization in the mouse (13). T<sub>FH</sub> cells do not produce Th cytokines such as IFN- $\gamma$ , IL-4, or IL-17 but likely mediate their function via CD40L and IL-21 (10–16). Although multiple functions have been ascribed to IL-21 in vitro, data from in vivo experiments indicate that it is critical for IgG production. IL-21R-deficient mice have decreased IgG1, IgG2b, and IgG3 levels, and IL-21R/IL-4 double-knockout mice have defects in the production of all switched isotypes, including IgG2a, although neither cytokine is necessary for the production of this isotype on its own (17). In vitro, IL-21 promotes B cell apoptosis in the presence of anti-IgM, though death can be rescued by anti-CD40 signaling (18, 19). Exogenous IL-21 promotes CSR and IgG secretion in vivo and in vitro and is a potent inducer of B lymphocyte-induced maturation protein 1 (16, 17, 20), and the ability of human T cells to induce Ig secretion is largely dependent on IL-21 (16, 21). These data are consistent with a role for IL-21 in T<sub>FH</sub> cell-mediated centrocyte selection and differentiation into plasma cells. Still, it is not yet clear if IL-21 functions primarily within or outside the GC, or both.

How Th cells promote antibody-forming cell (AFC) differentiation outside the follicle is poorly defined. In addition to seeding the GC, a subset of B cells at the interface of the T cell zone and follicle up-regulate CD138, migrate to the red pulp border, and form the extrafollicular focus. At this site, clumps of proliferative AFCs, or plasmablasts, undergo CSR and differentiation into long-lived plasma cells (6, 22, 23). Because T cell localization to the extrafollicular focus has not been reported, current models do not include a role for local T cell help in those responses (24). Instead, Th effects are thought to be exerted only before plasmablast migration from the T zone, though this idea has not been definitively demonstrated.

Clarifying the mechanics of the extrafollicular response is critical for understanding this important pathway for the production of autoantibodies. In normal mice, self-reactivity in B cells results in follicular exclusion and nonresponsiveness (25, 26), and provision of T cell help to such autoreactive cells leads to extrafollicular AFC differentiation rather than GC formation (27). A similar pattern of activation occurs

spontaneously in some autoimmune strains (27, 28), the most well-characterized example being the MRL/MpJ-*Fas*<sup>lpr</sup> (MRL<sup>lpr</sup>) model. In the spleens of MRL<sup>lpr</sup> mice, CXCR4<sup>+</sup> plasmablasts form defined proliferative extrafollicular foci at the border of the T cell zone before migrating to the red pulp, in the absence of GC development (29–32). This pattern of activation is in stark contrast to autoimmune sanroque mice, in which self-reactive T<sub>FH</sub> cells promote spontaneous GC development resulting in lupus-like pathology (33). Although IgG autoantibody production in MRL<sup>lpr</sup> mice is clearly T cell dependent (34, 35), the details of this process are poorly defined. In addition to CSR, the extrafollicular focus of MRL<sup>lpr</sup> mice is also a site for somatic hypermutation (30), a process that, in mammals, is dependent on T cell help (36). Importantly, how T cells support this GC-like activity outside the follicle is unclear. Recently, IL-21 has been shown to play a role in IgG autoantibody production and pathology in MRL<sup>lpr</sup> mice (37), though the relevant source of this cytokine remains loosely defined.

To investigate the mechanisms of T cell help for the extrafollicular autoantibody response genetically, we took advantage of the well-recognized requirement for the molecule inducible T cell co-stimulator (ICOS) for Th cell differentiation and IgG antibody responses. *Icos*-deficient (*Icos*<sup>−/−</sup>) animals have marked defects in GCs (38) and CSR to both IFN- $\gamma$ - and IL-4-dependent isotypes (39). A primary reason for these defects is that the development of T<sub>FH</sub> cells is ICOS dependent (13, 40, 41). Importantly, however, *Icos*<sup>−/−</sup> animals also have defects in IgG production early after immunization (42), suggesting that ICOS also plays a role in the extrafollicular response.

In this study, we find that *Icos* deficiency in MRL<sup>lpr</sup> mice causes an ontogenetic blockade of a population of effector T cells that down-regulate the surface glycoprotein P-selectin glycoprotein ligand 1 (PSGL-1). In addition to expressing CD40L, PSGL-1<sup>lo</sup> T cells are the sole producers of IL-21 and are uniquely able to induce IgG secretion in B cells in an IL-21- and CD40L-dependent manner. In their absence, plasmablast expression of activation-induced cytidine deaminase (AID) and extrafollicular development of IgG<sup>+</sup> plasma cells are impaired. A substantial fraction of PSGL-1<sup>lo</sup> T cells express CXCR4 and localize to the extrafollicular sites in both MRL<sup>lpr</sup> and other autoimmune mice, and thus constitute a population of Th cells anatomically distinct from T<sub>FH</sub> cells.

## RESULTS

### ICOS co-stimulation promotes isotype switching in the extrafollicular response

To assess the requirement for ICOS-dependent T cell help for the autoimmune extrafollicular response, we used intracellular staining to determine the number and isotype usage of plasma cells in the spleens of MRL<sup>lpr</sup> mice lacking the *Icos* gene. Spleen cells were stained for surface antigens and then fixed, permeabilized, and stained for both intracellular IgM and one of the four IgG isotypes. Plasma cells were identified by gating out TCR $\beta$ /CD3<sup>+</sup> and autofluorescent cells (*R3*), and then gating

on the  $B220^{lo}$   $CD138^{+}$  population (*R4*; Fig. 1 A), and region *R4* was analyzed for intracellular Ig expression. The percentage of plasma cells staining positive for each isotype (Fig. 1 B) as well as their absolute number (Fig. 1 D) are shown. Both groups had similar numbers of B cells (Fig. 1 C). Although *Icos*-deficient animals generated equivalent numbers of IgM-secreting cells as their age-matched controls, they failed to efficiently generate plasma cells expressing IgG1, IgG2a, IgG2b, and IgG3 (Fig. 1, B and D). These data were in close agreement with serum anti-double-stranded DNA antibody levels measured by isotype-specific ELISA (unpublished data), indicating that both Th1- and Th2-associated isotypes are ICOS dependent in this model.


Previous work has established that GCs are ICOS dependent (38, 39). To confirm previous reports that spontaneous GC formation is minimal in the spleens of *MRL<sup>lpr</sup>* mice (29–32), we determined the frequency of  $GL7^{hi}$   $IgK^{dull}$  B cells, a surface phenotype that corresponds to normal GC B cells in the response to nitrophenyl (NP)–chicken  $\gamma$  globulin (CGG; unpublished data). Although gut antigen–driven GC cells in Peyer's patches were abundant and robustly ICOS dependent (Fig. 2 A), as expected, we indeed observed very few GC B cells in the spleens of *MRL<sup>lpr</sup>* mice (Fig. 2 A). The  $GL7^{hi}$  IgK<sup>hi</sup> cells we observed and the few events falling in the GC gate are not reduced by *Icos* deficiency, and are unlikely to be true GC cells. In contrast, the spontaneous extrafollicular response is robust in these mice (30, 31). To address whether initiation of the extrafollicular response requires ICOS-de-

pendent T cell help, we analyzed the kinetics of early plasmablast development by gating on CD19 and determining the percentage of B cells expressing CD44 and CD138 (43). To our surprise, B cells in *Icos*-deficient animals up-regulated CD44 and CD138 with normal kinetics (Fig. 2, B and C), indicating that the loss of IgG<sup>+</sup> plasma cells is not caused by reduced plasmablast formation.

The normal induction of plasmablasts in knockout animals indicated that ICOS must promote IgG<sup>+</sup> plasma cell formation farther downstream in the extrafollicular response, possibly through induction of CSR. Because a limiting step in CSR is the expression of AID, we used quantitative PCR to measure the expression of *aicda*, the mRNA encoding AID, in sorted TCR $\beta^{-}$   $CD19^{+}$   $CD44^{hi}$   $CD138^{+}$  plasmablasts. We detected substantial expression of *aicda* in *Icos<sup>+/+</sup>* plasmablasts ( $\sim 40\%$  of the level in GC cells from NP-CGG–immunized B6 mice; not depicted), and this expression level was strikingly reduced by  $\sim 300$ -fold in *Icos<sup>-/-</sup>* plasmablasts (Fig. 2 D), indicating that ICOS is required for the induction of CSR in the extrafollicular pathway. Because we did not observe a concomitant increase in IgM<sup>+</sup> plasma cells with the decrease in post-switch cells in knockout animals (Fig. 1 D), it is likely that ICOS is also involved in the proliferation and/or survival of the cells that do undergo CSR.

#### ICOS is required for Th function and CXCR4 expression

The lack of IgG<sup>+</sup> plasma cells in mice lacking a CD4 T cell co-stimulator indicated a T cell defect ipso facto, so we proceeded




**Figure 1. ICOS is required for generation of IgG<sup>+</sup> plasma cells.** (A) Plasma cells were identified in the spleens of 23-wk-old *Icos<sup>+/+</sup>* and *Icos<sup>-/-</sup>* *MRL<sup>lpr</sup>* animals ( $n = 3$ –5 for two experiments) by expression of CD138 and down-regulation of B220 (*R4*) after exclusion of T cells and autofluorescent cells (*R3*). (B) The percentage of plasma cells within *R4* producing each antibody isotype are shown, as determined by intracellular Ig staining. Mean gate frequencies  $\pm$  SEM are shown. (C) Absolute number of  $CD90^{-}$   $CD19^{+}$  B cells in the spleen ( $n = 10$ –12). Horizontal bars indicate means. (D) Absolute numbers of plasma cells were calculated by multiplying the fraction of live single cells positive for each isotype by the total cell number. Data are expressed as means  $\pm$  SEM. \* $P < 0.05$  versus *Icos<sup>+/+</sup>* mice using the Mann-Whitney test.

to analyze the production of cytokines involved in the provision of B cell help, including the induction of CSR. To avoid the confounding relative increase in naive cells in the *Icos*<sup>−/−</sup> CD4 compartment (unpublished data), we sorted B220<sup>−</sup> TCR $\beta$ <sup>+</sup> CD4<sup>+</sup> CD44<sup>hi</sup> CD62L<sup>−</sup> effector T cells from knockout and control mice, cultured them with PMA and ionomycin for 24 h, and measured cytokine levels in the supernatants. *Icos*<sup>+/+</sup> naive cells were sorted from young MRL<sup>lpr</sup> mice and stimulated as a negative control, and robust IL-2 production verified their viability and function (Fig. 3 A). Although IL-2 production by effector T cells was unaffected by *Icos* deletion,


we observed a significant defect in the production of the B cell growth and switch factor IL-4 (Fig. 3 A). Production of other cytokines, including IFN- $\gamma$ , TNF- $\alpha$ , IL-5, and IL-10, was also substantially reduced (not depicted), reinforcing the view suggested by the plasma cell isotype data (Fig. 1 D) that ICOS does not promote Th skewing in mouse lupus but effector cytokine secretion in general.

Because IL-4<sup>−/−</sup> IL-13<sup>−/−</sup> mice are still capable of mounting an extrafollicular IgG1 response to NP-CGG (7), however, it seemed unlikely that the modest decrease in IL-4 production was solely responsible for the robust reduction in IgG1 AFCs that we observed. Another cytokine that can promote switching to IgG1 is IL-21 (17), and strikingly, the production of IL-21 was abolished in *Icos*-deficient cells (Fig. 3 A). IL-21 is a Th cytokine that signals through a  $\gamma_c$  chain cytokine receptor family member, and its role in B cell plasmagenesis and class switching has recently emerged (44). To directly assess the capacity of *Icos*<sup>−/−</sup> CD4 T cells to induce B cell class switching in culture, we sorted CD62L<sup>lo</sup> effectors, as described in the previous paragraph, and co-cultured them with sorted CD19<sup>+</sup> B220<sup>hi</sup> CD44<sup>lo</sup> naive B cells from young MRL<sup>lpr</sup> mice, with or without stimulation by anti-CD3 and anti-CD28 antibodies. Under these conditions, *Icos*<sup>−/−</sup> effectors were significantly less efficient at inducing B cell class switching as assessed by ELISA on the culture supernatants (Fig. 3 B), consistent with their impaired production of helper cytokines.

The inability of *Icos*<sup>−/−</sup> effectors to secrete IL-21 and efficiently promote IgG secretion was reminiscent of the finding that ICOS is required for T<sub>FH</sub> cell development in normal mice (40). Because the spleens of MRL<sup>lpr</sup> mice are nearly devoid of GCs, however, the defect we observed in extrafollicular class switching was conceptually inconsistent with a loss of T<sub>FH</sub> cells. Therefore, we hypothesized that specialized humoral effector T cells may also act in the extrafollicular focus. As T<sub>FH</sub> cells express CXCR5 in similar fashion to follicular B cells, thus colocalizing to their site of interaction, we speculated that a population of Th cells might colocalize with extrafollicular plasmablasts through expression of CXCR4. Therefore, we analyzed CXCR4 and CXCR5 expression on B220<sup>−</sup> CD4<sup>+</sup> splenocytes and found that, indeed, a substantial percentage of CD4 T cells expressed CXCR4. Further, this CXCR4<sup>+</sup> population was absolutely dependent on ICOS co-stimulation (Fig. 3 C). Conversely, CXCR5 expression was not only ICOS-independent but in fact elevated in its absence (Fig. 3 C). To interpret these data, it is important to consider that CXCR5 is not only expressed on T<sub>FH</sub> cells but is up-regulated on almost all CD4 T cells shortly after activation, mediating their initial localization to the T/B interface (45). Because CXCR5 expression in MRL<sup>lpr</sup> mice occurs largely on CD62L<sup>+</sup> effector cells (see Fig. 5), the accumulation of CXCR5<sup>+</sup> cells in *Icos*<sup>−/−</sup> mice likely represents effector cells in an early state of differentiation rather than T<sub>FH</sub> cells. Thus, these data suggest that this early migration program is unimpaired in the absence of ICOS but that further differentiation along an extrafollicular pathway is arrested. In combination with the defect in helper



**Figure 2. AID expression in extrafollicular plasmablasts, but not their formation, requires ICOS.** (A) Percentage of GL7<sup>hi</sup> Igκ<sup>lo</sup> GC B cells, gated on CD19, in the spleens (spl) and Peyer's patches (pp) of *Icos*<sup>+/+</sup> and *Icos*<sup>−/−</sup> MRL<sup>lpr</sup> mice ( $n = 4$ –5 for two experiments). (B) Percentage of CD44<sup>hi</sup> cells bearing the early plasmablast marker CD138 (reference 43) in the TCR $\beta$ <sup>+</sup> CD19<sup>+</sup> B cell compartment of 18-wk-old *Icos*<sup>+/+</sup> and *Icos*<sup>−/−</sup> mice ( $n = 4$ –6 for three experiments). (C) Percentage of CD90<sup>−</sup> CD19<sup>+</sup> B cells expressing CD138 and high levels of CD44 at the indicated ages ( $n = 4$ –14 per age group; three pooled experiments are shown). (D) Plasmablasts were sorted from *Icos*<sup>+/+</sup> and *Icos*<sup>−/−</sup> mice as gated in B, and expression of *aicda* mRNA encoding AID was determined by quantitative PCR (two pooled mice per experiment and two experimental replicates shown). All data are displayed as means  $\pm$  SEM. \* $P \leq 0.05$  versus *Icos*<sup>+/+</sup> mice using the Student's *t* test.




**Figure 3.** *Icos*<sup>-/-</sup> effector T cells have defects in cytokine production, helper function, and CXCR4, but not CXCR5, expression. (A) Sorted TCR $\beta$ <sup>+</sup> CD4<sup>+</sup> B220<sup>-</sup> CD44<sup>hi</sup> CD62L<sup>lo</sup> effector T cells from *Icos*<sup>+/+</sup> and *Icos*<sup>-/-</sup> mice were cultured with PMA and ionomycin for 24 h, and the indicated cytokines were measured in the supernatants. *Icos*<sup>+/+</sup> CD44<sup>hi</sup> CD62L<sup>hi</sup> naive T cells were stimulated as a control (representative of two experiments). (B) Effector CD4 cells were sorted as in A and cultured with sorted CD19<sup>+</sup> B220<sup>-</sup> CD90<sup>-</sup> CD44<sup>lo</sup> naive B cells from 8-wk-old mice in the presence or absence of anti-CD3 and anti-CD28. After 96 h, secreted IgG was measured in the culture supernatant (representative of three experiments). (C) Expression of CXCR4 and CXCR5 on CD4<sup>+</sup> B220<sup>-</sup> T cells from 20-wk-old mice was determined by FACS ( $n = 3$  for three experiments). The continuous line indicates specific staining, and the gray shading indicates isotype control. Values indicate the percent positive minus isotype control. All data are presented as means  $\pm$  SEM. \* $P \leq 0.05$  versus *Icos*<sup>+/+</sup> using the Student's *t* test.

function in vitro and reduction in AID expression in vivo, the loss of CXCR4 expression suggested strongly to us that ICOS is required for the development of a T<sub>FH</sub> cell-like CD4 effector subset that acts on plasmablasts.

#### Extrafollicular helper cells can be identified by down-regulation of PSGL-1

A parallel approach that we used to assess Th cell development in *Icos*<sup>-/-</sup> mice was to stain for other surface markers associated with Th cells in antibody responses. In the ovalbumin response, effector cells have been separated according to CD62L expression and P-selectin binding such that P-selectin

ligand<sup>+</sup> (P-lig<sup>+</sup>) cells mediate delayed-type hypersensitivity, whereas P-lig<sup>-</sup> CD62L<sup>lo</sup> cells induce IgG1 (46). P-lig, which is detected using a P-selectin–Ig fusion protein, is generated by carbohydrate modification of PSGL-1, whereas unmodified PSGL-1 expression does not confer P-selectin binding. Because PSGL-1 has been reported to be constitutively expressed by T cells, we were surprised to find that among CD4 T cells that were negative for P-lig, a minor subset also down-regulated the PSGL-1 scaffold altogether (Fig. 4 A). Down-regulation of PSGL-1 was limited to the CD44<sup>hi</sup> and CD62L<sup>lo</sup> subset (Fig. 4 C). Thus, CD44<sup>hi</sup> antigen-experienced CD4 T cells can be subdivided into three surface phenotypes according to



**Figure 4.** A novel population of CD4 T cells marked by PSGL-1 down-regulation requires both ICOS and B cells for their development. (A) B220<sup>-</sup> TCR $\beta$ <sup>+</sup> CD4<sup>+</sup> T cells from B6 and MRL<sup>lpr</sup> mice were stained with anti-PSGL-1 and a P-selectin–Ig fusion protein to detect P-lig. (B and C) TCR $\beta$ <sup>+</sup> B220<sup>-</sup> T cells were gated on CD4 or CD8, and CD4<sup>+</sup> cells were separated according to CD44 expression, as indicated, and the expression of PSGL-1 and CD62L was determined on these populations. (D) Expression of PSGL-1 and CD62L on CD4<sup>+</sup> B220<sup>-</sup> T cells from *Icos*<sup>+/+</sup> and *Icos*<sup>-/-</sup> mice was determined by FACS. Percentages are shown. (E) The percentages of CD4 T cells that had down-regulated PSGL-1 at 9 and 16 wk of age are shown ( $n = 4$ –7). (F) The percentage of PSGL-1<sup>lo</sup> T cells in 25-wk-old B cell-deficient *J<sub>H</sub>*<sup>-/-</sup> MRL<sup>lpr</sup> mice was compared with age-matched *J<sub>H</sub>*<sup>+/+</sup> controls ( $n = 3$ ). A–D show representative data from a minimum of five animals. Data in E and F are expressed as means  $\pm$  SEM. \* $P \leq 0.05$  compared with age-matched controls using the Student's *t* test.

the expression of CD62L and PSGL-1. CD8 T cells, in contrast, remain uniformly PSGL-1<sup>hi</sup> (Fig. 4 B).


PSGL-1<sup>lo</sup> CD4 cells increase in frequency in MRL<sup>lpr</sup> mice as disease progresses, reaching nearly 20% of the CD4 T cell compartment by 16 wk of age (Fig. 4 D). When we analyzed PSGL-1 expression on *Icos*<sup>-/-</sup> T cells, we found a marked reduction in the frequency of PSGL-1<sup>lo</sup> cells (Fig. 4, D and E) parallel to the loss of CXCR4 described in Fig. 3 C. Interestingly, the development of PSGL-1<sup>lo</sup> cells was also dependent on B cells, as MRL<sup>lpr</sup> mice bearing an Ig heavy chain deletion ( $J_H^{-/-}$ ) have a significant reduction in their numbers (Fig. 4 F). Further, CXCR4 expression was almost exclusively confined to the PSGL-1<sup>lo</sup> CD62L<sup>lo</sup> population, and these cells expressed low levels of CXCR5 (Fig. 5). The expression of CXCR5 that we observed in the CD62L<sup>+</sup> population is consistent with recent activation (45) rather than a T<sub>FH</sub> phenotype, which is CD62L<sup>lo</sup> (46). Although CXCR4, a coreceptor for HIV, is expressed broadly on human CD4 T cells, including GC T cells (47), it has not been well characterized in mouse T cells. Conditional deletion of CXCR4 in T cells does not affect GC formation, indicating that it is not critical for T<sub>FH</sub> cell function (48); the T cell–specific requirement for CXCR4 in the extrafollicular response was not addressed in that study.

Lymphocyte homing is not mediated solely by the acquisition of new chemokine receptors but also by modulation of expression or activity of competing receptors. Although nearly all CD4 T cells up-regulate CXCR5 after activation, CCR7 activity prevents the majority of these cells from localizing to the follicle (49). CCR7 levels were reduced on all CD44<sup>hi</sup> subsets, including PSGL-1<sup>lo</sup> cells, compared with naive cells (Fig. 5), though not to a striking extent. PSGL-1 itself has

recently been implicated in binding and chemotaxis to CCR7 ligands (50). To evaluate the chemotactic responses of PSGL-1<sup>lo</sup> T cells to CCR7, CXCR5, and CXCR4 ligands, we performed transmigration assays in vitro. As expected, all effector T cell subsets were less responsive to the CCR7 ligands CCL19 and CCL21 than their naive counterparts, with the PSGL-1<sup>lo</sup> subset migrating the least (Fig. 6). Loss of PSGL-1 may therefore contribute to egress from the T cell zone.

Importantly, no responsiveness to the B cell zone chemokine CXCL13, which acts through CXCR5, was observed in the PSGL-1<sup>lo</sup> subset despite robust migration by B cells (Fig. 6), indicating that they are not T<sub>FH</sub> cells. We initially presumed that the expression of CXCR4 in PSGL-1<sup>lo</sup> T cells would confer an enhanced chemotactic response to its ligand, CXCL12, but the regulation of responses to this chemokine in vitro are more complex. Plasma cells, which migrate in a CXCR4-dependent manner to sites rich in CXCL12, rapidly lose responsiveness to this chemokine in vitro despite high expression of its receptor (51, 52). Consistent with these reports, we observed depressed in vitro migration to CXCL12 in CD138<sup>+</sup> plasmablasts, and this reduction was mirrored in PSGL-1<sup>lo</sup> T cells (Fig. 6).

Although these data were consistent with the localization of PSGL-1<sup>lo</sup> T cells to niches high in CXCL12, such as extrafollicular foci and the red pulp, we proceeded to directly assess their splenic localization using immunofluorescence microscopy. The T cell zone is clearly identified by colocalization of PSGL-1 and CD4 (Fig. 7 B). Extrafollicular foci are identifiable as dense clusters of plasmablasts at the border of the T cell zone and red pulp, with plasmablasts being distinguished from follicular B cells both by high levels of IgM



**Figure 5. PSGL-1<sup>lo</sup> T cells have an extrafollicular chemokine receptor profile.** Expression levels of the chemokine receptors CXCR4, CXCR5, and CCR7 were compared between naive CD4 T cells and three subsets of CD44<sup>hi</sup> effector cells gated according to the expression of CD62L and PSGL-1, as in Fig. 4 C ( $n = 3$  for three experiments). Specific staining is indicated by the solid line, and isotype control staining is indicated by the gray shading. For CXCR4 and CXCR5, values indicate the mean percent positive minus isotype control  $\pm$  SEM. For CCR7, values are the mean fluorescence intensity  $\pm$  SEM. \*,  $P < 0.05$  compared with all other groups using the Student's *t* test.

staining and loss of B220 (Fig. 7 A). Using the image processing software ImageJ, we were able to enumerate the frequency of PSGL-1<sup>hi</sup> and PSGL-1<sup>lo</sup> T cells in the T cell zone, extrafollicular foci, and red pulp. In contrast to PSGL-1<sup>hi</sup> T cells, which were abundant in the T cell zone and rare at other sites, PSGL-1<sup>lo</sup> T cells were found at the greatest density in extrafollicular foci, though they also present to a lesser extent in the T cell zone and red pulp (Fig. 7 G). The extrafollicular localization of PSGL-1<sup>lo</sup> T cells was determined not only by their occurrence outside of B220<sup>+</sup> follicles and CD4-dense T cell zones, but by their occurrence at the edge of the T cell zone and red pulp as defined by staining of F4/80<sup>+</sup> red pulp macrophages (Fig. 7, D–F). Extrafollicular T cells lacking PSGL-1 were also readily identified using antibodies against TCR $\beta$  (unpublished data). In contrast to the cells in the T cell zone, of which only a minority are PSGL-1<sup>lo</sup>, T cells found in extrafollicular foci and in the red pulp were almost exclusively PSGL-1<sup>lo</sup> (Fig. 7 H), confirming that extrafollicular localization is tightly associated with the loss of PSGL-1.

### PSGL-1<sup>lo</sup> cells are functionally specialized to drive IgG production


Because we had described a defect in Th function in vitro and in vivo associated with the loss of CXCR4<sup>+</sup> PSGL-1<sup>lo</sup> T cells in the setting of *Icos* deficiency, we wanted to directly address whether the loss of PSGL-1 identifies effector T cells with specialized B helper functions. To this end, we analyzed their cytokine production by sorting CD44<sup>hi</sup> naive and CD44<sup>lo</sup> effector cells, the latter separated further according to their expression of CD62L and PSGL-1. Consistent with the involvement of IL-4 and IFN- $\gamma$  in CSR, both of these cytokines were made by PSGL-1<sup>lo</sup> cells but were also made by other effector subsets (Fig. 8 A), as would be expected given their pleiotropic nature. Similarly, CD40L was expressed on CD62L<sup>lo</sup> cells of both PSGL-1<sup>hi</sup> and PSGL-1<sup>lo</sup> phenotypes (Fig. 8 B), consistent with the role of this effector molecule in both humoral and inflammatory responses. In striking contrast, IL-21 was secreted exclusively by PSGL-1<sup>lo</sup> cells (Fig. 8 A).

Given the corresponding defects in the differentiation of PSGL-1<sup>lo</sup> cells and IgG<sup>+</sup> plasma cells we observed in *Icos*<sup>−/−</sup> mice, we proceeded to test directly whether PSGL-1<sup>lo</sup> cells were able to induce IgG class switching and secretion by co-culturing sorted naive B cells with anti-CD3/-CD28-stimulated sorted effector T cell subsets. Although other effector subsets had little effect, activated CD62L<sup>lo</sup> PSGL-1<sup>lo</sup> cells were sufficient to robustly induce isotype switching and secretion of IgG, to an even greater extent than an optimal dose of anti-CD40 and IL-4 (Fig. 8 C). Given the unique ability of PSGL-1<sup>lo</sup> cells to both make IL-21 and drive IgG secretion, as well as the emerging role for IL-21 in class switching and plasmagenesis, we hypothesized that IL-21 was important for their helper function. Indeed, the addition of IL-21 neutralizing antibody to co-cultures of PSGL-1<sup>lo</sup> cells and B cells significantly impaired IgG production in a dose-dependent manner (Fig. 8 D), confirming the important role for this cytokine in the collaboration of extrafollicular Th cells

with B cells. Further, CD40L is known to play a critical role in T/B collaboration in MRL<sup>lpr</sup> mice, and as expected, the addition of CD40L blocking antibody MR1 completely ablated the ability of PSGL-1<sup>lo</sup> helper cells to induce IgG production (Fig. 8 E).

### Extrafollicular Th cells occur in other autoimmune models

Because the MRL<sup>lpr</sup> model is rather unique in the extent of the dominance of the extrafollicular pathway over the GC, it



**Figure 6.** PSGL-1<sup>lo</sup> T cells from MRL<sup>lpr</sup> mice have chemotactic properties consistent with extrafollicular localization. Migration of T cell subsets or control populations to the ligands for CCR7 (CCL19 and CCL21), CXCR5 (CXCL13), and CXCR4 (CXCL12) in a Transwell chemotaxis assay. Error bars indicate means  $\pm$  SEM, and results are representative of three experiments. \*, P < 0.05 compared with CD62L<sup>lo</sup> PSGL-1<sup>hi</sup> cells using the Student's *t* test.


remained a possibility that the development of extrafollicular Th cells was limited to these mice. Thus, we analyzed two additional models: (NZB/BINJ  $\times$  NZW/LacJ) F1 (NZB/W F1) spontaneously lupus-prone mice, as well as rat insulin promoter-driven lymphotxin  $\alpha$  and  $\beta$  (RIP-LT $\alpha\beta$ ) transgenic mice, a genetically and mechanistically unrelated model of chronic inflammation. NZB/W F1 mice differ from MRL $^{lpr}$  mice in that they develop robust spontaneous GCs with age (32, 53), though both follicular and extrafollicular activation pathways are likely operative (54). RIP-LT $\alpha\beta$  mice express both LT $\alpha$  and LT $\beta$  in the pancreas, kidneys, and skin, leading to massive infiltrates in these tissues (55, 56).

Analysis of the spleens of both NZB/W F1 and RIP-LT $\alpha\beta$  mice revealed a striking age-dependent expansion of PSGL-1 $^{\text{lo}}$  CD4 T cells (Fig. 9 A). Further, as in MRL $^{lpr}$  animals, CXCR4 was expressed specifically within the PSGL-1 $^{\text{lo}}$  population (Fig. 9, B–D). However, PSGL-1 $^{\text{lo}}$  cells from NZB/W F1 and RIP-LT $\alpha\beta$  mice also contained a CXCR5 $^+$  T $_{\text{FH}}$  cell population (Fig. 9, B–D). These data suggested that Th cells with either a follicular or extrafollicular homing pattern could be identified within the PSGL-1 $^{\text{lo}}$  subset of other autoimmune models. Confirming the extrafollicular homing

pattern, Th cells were readily identified in the splenic extrafollicular foci of both NZB/W and RIP-LT $\alpha\beta$  mice by immunofluorescence microscopy (Fig. 9, E and F; and not depicted). As in the MRL $^{lpr}$  strain, single-cell analysis of the immunofluorescence images indicated that T cells found in extrafollicular sites were almost exclusively PSGL-1 $^{\text{lo}}$ , whereas those in the T cell zone were predominantly PSGL-1 $^{\text{hi}}$ . Thus, Th cells with a PSGL-1 $^{\text{lo}}$  phenotype occur at high frequency in multiple autoimmune models, a subset of which can be found in extrafollicular regions.

## DISCUSSION

The extrafollicular response is the dominant pathway of autoantibody production in the MRL $^{lpr}$  mouse, and we find that ICOS functions in this pathway through the induction of a population of Th cells that traffics to extrafollicular focus. Although the contribution of ICOS to GC responses has received significant attention, its role in extrafollicular responses has been neglected despite an early report that IgG production the first week after immunization, largely derived from the extrafollicular response, is ICOS dependent (42). We have recapitulated these results in our own laboratory, where




**Figure 7. PSGL-1 $^{\text{lo}}$  T cells localize to the extrafollicular focus.** Four-color immunofluorescence microscopy was used to determine the expression of PSGL-1 on CD4 T cells in extrafollicular sites. For clarity, each panel displays two or three of the four channels. One field is represented in A–C, and another is represented in D–F. In all panels, red and blue signals indicate PSGL-1 and IgM staining, respectively. Green indicates B220 in A, F4/80 in D, and CD4 in B and E, and is left blank in C and F. White arrows highlight the location of extrafollicular CD4 $^+$  cells. Bar, 100  $\mu\text{m}$ . (G and H) Enumeration of CD4 T cells expressing or lacking PSGL-1 in splenic T cell zones, extrafollicular sites, and the red pulp. The number of cells per millimeter squared in each site (G) and the percentage of CD4 $^+$  cells lacking PSGL-1 at each site (H) were determined from immunofluorescence micrographs. 100–300 cells, from multiple sections, were scored per mouse,  $n = 4$ . \*  $P < 0.05$  compared with the T cell zone. EF, extrafollicular focus; RP, red pulp; TZ, T cell zone.

the percentage of CD19<sup>+</sup> CD138<sup>+</sup> surface IgG1<sup>+</sup> plasmablasts 6 d after NP-CGG/alum immunization was substantially reduced in B6 *Icos ligand*<sup>-/-</sup> mice versus B6 controls (0.14 ± 0.11% vs. 1.87 ± 0.85%, respectively).

The ICOS-dependent Th cells that traffic to extrafollicular sites in MRL<sup>lpr</sup> mice were isolated and characterized based on their down-regulation of PSGL-1, though their essential features are expression of CXCR4, localization to the extrafollicular sites and B cell helper activity. Among the many effector cells that are generated in MRL<sup>lpr</sup> mice, the relatively small PSGL-1<sup>lo</sup> subset is remarkably unique in its ability to induce IgG secretion. One effector mechanism that is important for this function is the secretion of IL-21, an IL-2 family member previously shown to cooperate with IL-4 for IgG antibody production (17). IL-21 has been implicated in GC responses, and there is also data to suggest that it functions in the extrafollicular pathway. Although extrafollicular isotype switching to IgG1 in response to NP-CGG can occur even in the dual absence of IL-4 and IL-13 (7), this early IgG1 production is completely blocked in IL-4<sup>-/-</sup> IL-21R<sup>-/-</sup> double-knockout mice (17). Thus, CXCR4<sup>+</sup> extrafollicular

Th cells might be a source of IL-21 in the normal extrafollicular IgG1 response. Our observation that PSGL-1<sup>lo</sup> T cells from MRL<sup>lpr</sup> mice, in contrast to T<sub>FH</sub> cells (10–12), also secrete IL-4 and IFN- $\gamma$  raises the possibility that isotype instruction by these switch cytokines may continue in the extrafollicular focus. Clarification of this point will require both single-cell analysis of cytokine production within the PSGL-1<sup>lo</sup> subset and histological examination of the location of IL-21 production. The former experiment has been hampered by the lack of an intracellular staining reagent for IL-21, and both experiments may be precisely addressed with an IL-21 reporter mouse.

PSGL-1 has been sensibly thought to be constitutively expressed on T cells, because P-selectin binding is regulated not by PSGL-1 expression but by inducible glycosyltransferases that modify the PSGL-1 glycoform (57). We were surprised, therefore, to identify a population of activated CD4 T cells that had down-regulated the entire, presumably inactive, glycoprotein scaffold. Recently, however, PSGL-1 was also shown to participate in chemotactic responses to CCR7 ligands (50), providing a mechanistic reason why humoral effector T cells, which must leave the T cell zone to enter follicular or extrafollicular




**Figure 8. PSGL-1<sup>lo</sup> T cells are unique in their ability to promote IgG secretion via IL-21.** (A) TCR $\beta$ <sup>+</sup> CD4<sup>+</sup> B220<sup>-</sup> CD44<sup>hi</sup> effector cells were separated according to their expression of CD62L and PSGL-1 and were cultured with PMA and ionomycin for 24 h, and the indicated cytokines were measured in the supernatants. CD44<sup>lo</sup> CD62L<sup>hi</sup> naive T cells were stimulated as a negative control. Results are representative of three experiments. (B) Percent expression of CD40L on the indicated subsets was determined by FACS ( $n = 3$ ). Specific staining is indicated by a continuous line, and isotype control staining is indicated by gray shading. (C) Effector CD4 cells were sorted as in A and cultured with sorted CD19<sup>+</sup> B220<sup>+</sup> CD90<sup>-</sup> CD44<sup>hi</sup> naive B cells from young mice in the presence or absence of anti-CD3 and anti-CD28. After 96 h, secreted IgG was measured in the culture supernatant. B cell stimulation with an optimal dose of anti-CD40 with or without IL-4 is shown for comparison. Results are representative of three experiments. (D) IL-21 blocking antibody was added at fourfold increasing concentrations to a co-culture of naive B cells with PSGL-1<sup>lo</sup> effector cells. Isotype control antibody was added at maximum concentration. (E) CD40L blocking antibody MR1 or isotype control was added to similar co-cultures. D and E are representative of two experiments each. All data are shown as means ± SEM. \*, P < 0.05 compared with other effector subsets (A and C) or isotype control (D and E) using the Student's *t* test.

sites, down-regulate this molecule. Supporting a connection between PSGL-1 down-regulation and humoral effector function, CD4 T cells that are actively translating IL-4 protein in the lymph nodes of helminth-infected mice, as opposed to tissue-tropic effector cells requiring peripheral restimulation, also have a PSGL-1<sup>lo</sup> phenotype (58).

In the MRL<sup>lpr</sup> autoantibody response, in which the extrafollicular pathway dominates, PSGL-1<sup>lo</sup> humoral effector T cells express CXCR4 and localize to the extrafollicular focus. In contrast, PSGL-1<sup>lo</sup> cells from NZB/W F1 and RIP-LT $\alpha\beta$  transgenic mice, which develop both extrafollicular and GC responses, were found to have both CXCR4- and CXCR5-expressing cells. Indeed, the expression of CXCR5, like CXCR4, was largely restricted to this population, indicating

that the T<sub>FH</sub> cell subset also bears a PSGL-1<sup>lo</sup> phenotype. The follicular versus extrafollicular trafficking pattern of Th cells may be instructed by their cognate B cells, the latter differentiating along the GC or plasmablast pathway, as determined by factors such as strength of the BCR signal (59).

The effector mechanisms we defined for extrafollicular PSGL-1<sup>lo</sup> cells from MRL<sup>lpr</sup> mice, IL-21 and CD40L, are also shared by T<sub>FH</sub> cells (10, 14). These common features are not surprising given that T cell-dependent CSR and plasmagenesis occur in both GC B cells and plasmablasts, and both IL-21 and CD40L regulate these processes. It is possible that the more distinct features of follicular versus extrafollicular responses, however, such as long-lived plasma cell and memory formation, may in part reflect unique products of follicular versus



**Figure 9. PSGL-1<sup>lo</sup> extrafollicular T cells occur in other autoimmune models.** (A) The percentage of CD44<sup>hi</sup> PSGL-1<sup>lo</sup> cells within the CD4 T cell compartment of RIP-LT $\alpha\beta$  and NZB/W F1 mice. 6–10 mice at varying ages were analyzed, and representative plots of the indicated ages are shown. (B and C) Expression of CXCR5 and CXCR4 on PSGL-1<sup>lo</sup> cells from 24-wk-old RIP-LT $\alpha\beta$  (B) and 46-wk-old NZB/W F1 (C) mice. Continuous lines indicate PSGL-1<sup>lo</sup> effectors, gray-shaded histograms indicate CD44<sup>lo</sup> CD62L<sup>hi</sup> naive CD4 T cells, and dotted lines indicate B cells. An MRL<sup>lpr</sup> control was stained concomitantly with the RIP-LT $\alpha\beta$  group; profiles may also be compared with Fig. 5. Gate frequencies above background are shown. (D) Plots of CXCR5 and CXCR4 expression on effector subsets separated by CD62L and PSGL-1 expression. \*, P < 0.05 compared with PSGL-1<sup>hi</sup> effector subsets using the Student's t test. (E and F) The number of cells per millimeter squared in each site in RIP-LT $\alpha\beta$  (E) and NZB/W F1 (F) spleens were determined from immunofluorescence micrographs as in Fig. 7. 100–300 cells across multiple sections were counted per mouse (n = 4–6 mice per group). \*, P < 0.05 compared with the T cell zone using the Student's t test. EF, extrafollicular focus; TZ, T cell zone.

extrafollicular helper cells that have yet to be defined. Alternatively, the helper cells that support extrafollicular responses may not be ontogenetically or mechanistically distinct from  $T_{FH}$  cells but simply exhibit an alternative trafficking pattern. Illuminating the relationships between these humoral effector cells will be aided by global comparison of their effector genes and lineage specification factors. In microarray experiments,  $T_{FH}$  cells have been shown to express B cell leukemia/lymphoma 6 (14), an essential transcription factor in GC B cells (60). Whether non- $T_{FH}$  PSGL-1<sup>lo</sup> T cells from MRL<sup>lpr</sup> mice also express this transcription factor is currently under investigation.

Based on our data that PSGL-1<sup>lo</sup> CD4 T cells are absent in both *Icos* mutant and B cell-deficient mice, we propose that the ICOS–B7-related protein 1 interaction during T/B collaboration provides one of the critical signals for the development of humoral effector cells. Our observation that *Icos*<sup>−/−</sup> effectors are still reasonably potent at providing B cell help in culture may be attributed to the minimal requirements, such as CD40L and IL-4, for IgG induction in vitro. An alternative, though not exclusive, explanation is that humoral effector T cells fail to migrate appropriately to sites of B cell differentiation in vivo. In this view, the lack of PSGL-1<sup>lo</sup> cells could reflect a failure of humoral effector cells to down-regulate PSGL-1, rather than fail to develop *per se*, an interpretation that would be consistent with the reduced CXCR4 expression we observed in *Icos*<sup>−/−</sup> effectors. The severe defect in IL-21 secretion, however, indicates a broader block in helper cell differentiation. Still, whether ICOS provides a specific differentiation signal or simply allows humoral effector cells to expand and survive is not clear. In addition, signaling to B cells through the ICOS ligand, B7-related protein 1, itself could potentially regulate plasma cell differentiation, complementing the activity of IL-21 and CD40L. To what extent PSGL-1<sup>lo</sup> T cell effects on plasmablasts, such as AID induction, occur within the extrafollicular focus itself versus earlier at the T/B interface remains undefined.

Functional characteristics such as cytokine production are commonly used to stratify effector CD4 T cells such as Th1, Th2, or Th17.  $T_{FH}$  cells, in contrast, are defined essentially by their trafficking pattern, though with a view to their functional specialty. We have characterized a novel population of B Th cells that occur in chronic autoimmunity that do not conform to effector cell categories as currently defined. It remains to be clarified whether these extrafollicular Th cells merit designation as a subset distinct from their follicular counterparts, or rather are  $T_{FH}$  cells that are recruited to an alternative site of B cell activation in an autoimmune setting.

## MATERIALS AND METHODS

**Mice.** MRL<sup>lpr</sup> animals were obtained from the Jackson Laboratory and were maintained in specific pathogen-free conditions at the Yale School of Medicine. RIP-LT $\alpha\beta$  transgenic mice (55) were provided by R. Mounzer and N. Ruddle (Yale School of Medicine, New Haven, CT). Spleens from NZB/W F1 mice were provided by A. Davidson (Feinstein Institute for Medical Research, Manhasset, NY). The Institutional Animal Care and Use Committee of Yale University approved all procedures. The disrupted *Icos* allele was generated as described previously (61), and was backcrossed to the

MRL<sup>lpr</sup> background for six generations and intercrossed, and MRL<sup>lpr, Icos</sup><sup>−/−</sup> mice were subsequently maintained as homozygotes. The MHC and four non-MHC autoimmune susceptibility loci (B6-derived *Lmb1* and MRL-derived *Lmb2*, *Lmb3*, and *Lmb4*) are discernable in the MRL<sup>lpr</sup> and B6<sup>lpr</sup> genomes (62, 63). At the N6 generation, markers that define each of these intervals (*D4Mit17*, *D4Mit9*, *D4Mit146*, *D4Mit12*, *D4Mit33*, *D5Mit145*, *D5Mit13*, *D5Mit356*, *D5Mit24*, *D7Mit57*, *D7Mit82*, *D7Mit211*, *D7Mit147*, *D7Mit39*, *D10Mit51*, *D10Mit15*, *D10Mit11*, *D10Mit269*, *D17Mit16*, and *Tijf*) revealed that *Icos*<sup>−/−</sup> and control groups were fixed for the MRL genome at all intervals except the centromeric region of *Lmb1* (Table S1, available at <http://www.jem.org/cgi/content/full/jem.20080840/DC1>). Because MRL<sup>lpr</sup> mice carrying the B6 allele of *Lmb1* have slightly increased splenic lymphoproliferation, but autoantibody production is unaffected (62), *Lmb1* has a minimal impact on the development of autoimmunity. Moreover, if anything, the B6 allele contributes to an increase in lymphocyte activation and so would not invalidate our conclusions; thus, the impact of *Icos* deficiency may actually be slightly stronger than we describe.

In all experiments, precisely age- and sex-matched controls were included with experimental animals. In experiments with mixed-sex groups, both groups contained the same ratio of males and females.

**Flow cytometry.** Spleens were extracted and homogenized by pressing through a 40- $\mu$ M nylon filter. Red blood cells were lysed by hypotonic shock by brief exposure to distilled water followed by immediate isotonic restoration with 10 $\times$  PBS. Surface staining was performed in ice-cold PBS with 1% FCS in the presence of FcR blocking antibody 2.4G2. For experiments involving chemokine receptor staining, antibody-labeled cells were placed at 37°C for 30 min, washed, and incubated with streptavidin-conjugated fluorophore on ice. With the exception of intracellular Ig staining, samples were analyzed unfixed, and dead cells were excluded based on staining with Hoechst 33342 (Sigma-Aldrich) added immediately before analysis. For intracellular Ig staining, cells were stained for surface antigens as described, fixed with a 1:4 dilution of Cytofix/Cytoperm (BD) in PBS for 20 min on ice, washed, blocked with 5% rat serum in Perm/Wash (BD), and incubated with anti-mouse Ig antibodies in Perm/Wash overnight at 4°C. In all experiments, cells were resuspended in PBS and analyzed on a four-laser flow cytometer (LSRII; BD). Antibody clones used were anti-mouse IgG1 (15H6; SouthernBiotech), IgG2a (R19-15; BD), IgG2b (R12-3; BD), IgG3 (R40-82; BD), IgM (gift of M. Shlomchik, Yale School of Medicine, New Haven, CT), TCR $\beta$  (H57-587; BD), CD3 (145-2C11; BD), CD138 (281-2; BD), PSGL-1 (2PH-1; BD), B220 (RA3-6B2; BD), CD19 (1D3; BD), CD44 (IM7; eBioscience), CD62L (MEL-14; BD), CXCR4 (2B11; BD), CXCR5 (2G8; BD), and CCR7 (4B12; eBioscience). The fluorochromes used in each channel were FITC or AF488, PE, PE-Texas red, PE-Cy7, allophycocyanin (APC) or AF647, APC-Cy7 or APC-AF750, Hoechst 33342, and Pacific blue.

**Quantitative PCR.** Total RNA was isolated from sorted TCR $\beta$ <sup>+</sup> CD19<sup>+</sup> CD44<sup>hi</sup> CD138<sup>+</sup> plasmablasts using the RNeasy Mini kit (QIAGEN) and treated with amplification grade DNase I (Invitrogen). 0.5  $\mu$ g RNA was reversed transcribed with Superscript III (Invitrogen) using random hexamers, and the cDNA was subjected to real-time PCR using Taqman probes, Hot-Start Taq DNA polymerase (QIAGEN), and a thermocycler (3000XP; Stratagene). 10-fold serial dilutions of *aicda* (gift of V. Odegard and D. Schatz, Yale School of Medicine, New Haven, CT) and *actin* standard were included to generate standard curves. Starting cDNA quantity was calculated from *ct* values relative to the standard curve. The amount of *aicda* was normalized to the amount of actin in each sample. Forward primer, reverse primer, and probe sequences were as follows: *aicda*, 5'-CGGCTAACAGACAACCTCG-3', 5'-GCATCTCGCAAGTCATCGA-3', and FAM-CGC-ATCCTTTGCCCTGTACGA-TAMRA; and *actin*, 5'-AGAGGGAAA-TCGTGCGTGAC-3', 5'-CAATAGTGTGACCTGGCCGT-3', and FAM-CACTGCCGATCCTCTCCCTCCC-TAMRA.

**Cytokine measurements.** Effector T cells were sorted as indicated in the figures and cultured with 50 ng/ml PMA and 1  $\mu$ M ionomycin for 24 h in

complete Click's media. IFN- $\gamma$ , IL-4, IL-2, and IL-17 from culture supernatants were measured by a Luminex assay using anti-mouse cytokine beads (Beadlyte; Millipore). IL-21 was detected by sandwich ELISA as follows: Immulon-4 HBX (Millipore) plates were coated with anti-mouse IL-21 (R&D Systems), and bound IL-21 from culture supernatants was detected using biotinylated anti-mouse IL-21 (R&D Systems) followed by Extravidin-horseradish peroxidase (Sigma-Aldrich). Before analysis, supernatants were concentrated ninefold in 5-kD-cutoff Amicon Ultra-4 columns (Millipore).

**Chemotaxis assay.** Splenocytes were isolated in prewarmed serum-free RPMI 1640 with 0.5% BSA and 2 mM HEPES, and  $10^6$  cells in 100  $\mu$ l were added to the upper chamber of 5- $\mu$ M Transwell plates (Millipore) containing 500  $\mu$ l of media in the lower chamber. Cells were preincubated for 1 h at 37°C in 5% CO<sub>2</sub>, and chemokines were added in 100  $\mu$ l to the lower chamber and cells were allowed to migrate for 2 h. The percent migration was calculated by dividing the number recovered in the lower chamber by the number of input for each population. Specific migration was determined by subtracting the percent migrated without chemokine. Samples were run in duplicate at three chemokine dilutions. Results from the optimal chemokine concentration are shown in the figures and were as follows: 25 ng/ml CCL19, 100 ng/ml CCL21, 250 ng/ml CXCL12, and 3  $\mu$ g/ml CXCL13.

**B cell help assay.** CD44<sup>lo</sup> B220<sup>+</sup> CD19<sup>+</sup> naive B cells were sorted from 8-wk-old mice.  $6 \times 10^5$  sorted effector T cells were cultured with  $2 \times 10^5$  B cells in 600  $\mu$ l of complete Click's media in a 48-well plate. Some wells were precoated with 20  $\mu$ g/ml anti-CD3, and 1  $\mu$ g/ml anti-CD28 was added in suspension. As a control, cells were stimulated with 10  $\mu$ g/ml anti-CD40 with or without 50 ng/ml IL-4. Secreted IgG was measured in the culture supernatant after 96 h. IL-21 blocking antibody or isotype control (R&D Systems) were added at fivefold increments up to 50  $\mu$ g/ml. CD40L blocking antibody (clone MR1; BD) was added at 200 ng/ml.

**Immunofluorescence microscopy.** Spleens were snap frozen in optimal cutting temperature, cut into 6- $\mu$ M sections, and fixed with ice-cold acetone. Rehydrated sections were blocked with 5% rat serum, 5% rabbit serum, and 3% BSA with 0.1% Tween, and stained with antibodies, including B220 (RA3-6B2; BD), IgM (R6-602; BD), IgM-AF647 (gift of M. Shlomchik), PSGL-1 (4RA10 or KPL-1; BD), TCR $\beta$  (H57-597; eBioscience), F4/80 (BM8; eBioscience), and CD4 (RM4-5; eBioscience). Secondary detection was performed with anti-FITC-AF488 (Invitrogen), streptavidin-Cy3 (Jackson ImmunoResearch Laboratories), or streptavidin-AF647 (Invitrogen). Images were collected on a laser-scanning confocal microscope (model 510 META; Carl Zeiss, Inc.). Individual channels were uploaded into ImageJ software (available at <http://rsb.info.nih.gov/ij/index.html>). CD4<sup>+</sup> single cells were scored for their expression of PSGL-1 using the "ColocalizeRGB" and "Cell counter" plugins (default settings). Extrafollicular foci were defined as dense clusters of IgM<sup>hi</sup> B220<sup>+</sup> plasmablasts near the border of T cell zones. The red pulp was defined as the remaining area outside T cell zones, B cell follicles, and extrafollicular foci, and was confirmed on separate sections to display expression for F4/80.

**Statistical analysis.** All data analysis was performed using Prism 4.0a (GraphPad Software, Inc.). In most cases, two-tailed p-values were calculated by the unpaired Student's *t* test. For populations that were unlikely to approximate a Gaussian distribution, two-tailed p-values were calculated using the Mann-Whitney test.

**Online supplemental material.** Table S1 shows the genotypes of microsatellite markers within autoimmune susceptibility loci of a sampling of mice used in the study. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20080840/DC1>.

We thank A. Rudensky for supporting J.M. Odegard during the revision of this manuscript. We are grateful to M. Shlomchik for providing the anti-IgM antibody, V. Odegard and D. Schatz for the *aicda* probe and PCR conditions, R. Mounzer and

N. Ruddle for RIP-LT $\alpha$  $\beta$  transgenic mice, Anne Davidson for spleens of NZB/W F1 animals, and S. Kaech and A. Rudensky for their thoughtful comments.

This work was supported by National Institutes of Health Grants AR40072 and AR44076, and by generous support from Rheuminations, Inc., the Arthritis Foundation, and the Connecticut Chapter of the Lupus Foundation of America.

The authors declare that they have no financial conflicts of interest.

Submitted: 18 April 2008

Accepted: 9 October 2008

## REFERENCES

1. Reinhardt, R.L., S.J. Kang, H.E. Liang, and R.M. Locksley. 2006. T helper cell effector fates—who, how and where? *Curr. Opin. Immunol.* 18:271–277.
2. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu. Rev. Immunol.* 7:145–173.
3. Abbas, A.K., K.M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. *Nature*. 383:787–793.
4. Kaplan, M.H., U. Schindler, S.T. Smiley, and M.J. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. *Immunity*. 4:313–319.
5. Okada, T., and J.G. Cyster. 2006. B cell migration and interactions in the early phase of antibody responses. *Curr. Opin. Immunol.* 18:278–285.
6. Toellner, K.M., S.A. Luther, D.M. Sze, R.K. Choy, D.R. Taylor, I.C. MacLennan, and H. Acha-Orbea. 1998. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. *J. Exp. Med.* 187:1193–1204.
7. Cunningham, A.F., P.G. Fallon, M. Khan, S. Vacheron, H. Acha-Orbea, I.C. MacLennan, A.N. McKenzie, and K.M. Toellner. 2002. Th2 activities induced during virgin T cell priming in the absence of IL-4, IL-13, and B cells. *J. Immunol.* 169:2900–2906.
8. Takahashi, Y., P.R. Dutta, D.M. Cerasoli, and G. Kelsoe. 1998. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. *J. Exp. Med.* 187:885–895.
9. MacLennan, I.C. 1994. Germinal centers. *Annu. Rev. Immunol.* 12: 117–139.
10. Breitfeld, D., L. Ohl, E. Kremmer, J. Ellwart, F. Sallusto, M. Lipp, and R. Forster. 2000. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. *J. Exp. Med.* 192:1545–1552.
11. Scherli, P., K. Willimann, A.B. Lang, M. Lipp, P. Loetscher, and B. Moser. 2000. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. *J. Exp. Med.* 192:1553–1562.
12. Kim, C.H., L.S. Rott, I. Clark-Lewis, D.J. Campbell, L. Wu, and E.C. Butcher. 2001. Subspecialization of CXCR5<sup>+</sup> T cells: B helper activity is focused in a germinal center-localized subset of CXCR5<sup>+</sup> T cells. *J. Exp. Med.* 193:1373–1381.
13. Nurieva, R.I., Y. Chung, D. Hwang, X.O. Yang, H.S. Kang, L. Ma, Y.H. Wang, S.S. Watowich, A.M. Jetten, Q. Tian, and C. Dong. 2008. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. *Immunity*. 29:138–149.
14. Chtanova, T., S.G. Tangye, R. Newton, N. Frank, M.R. Hodge, M.S. Rolph, and C.R. Mackay. 2004. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. *J. Immunol.* 173:68–78.
15. Kim, C.H., H.W. Lim, J.R. Kim, L. Rott, P. Hillsamer, and E.C. Butcher. 2004. Unique gene expression program of human germinal center T helper cells. *Blood*. 104:1952–1960.
16. Bryant, V.L., C.S. Ma, D.T. Avery, Y. Li, K.L. Good, L.M. Corcoran, R. de Waal Malefyt, and S.G. Tangye. 2007. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5<sup>+</sup> T follicular helper cells. *J. Immunol.* 179:8180–8190.
17. Ozaki, K., R. Spolski, C.G. Feng, C.F. Qi, J. Cheng, A. Sher, H.C. Morse III, C. Liu, P.L. Schwartzberg, and W.J. Leonard. 2002. A critical role for IL-21 in regulating immunoglobulin production. *Science*. 298:1630–1634.

18. Parrish-Novak, J., S.R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J.A. Gross, J. Johnston, K. Madden, W. Xu, J. West, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. *Nature*. 408:57–63.

19. Mehta, D.S., A.L. Wurster, M.J. Whitters, D.A. Young, M. Collins, and M.J. Grusby. 2003. IL-21 induces the apoptosis of resting and activated primary B cells. *J. Immunol.* 170:4111–4118.

20. Pene, J., J.F. Gauchat, S. Lecart, E. Drouet, P. Guglielmi, V. Boulay, A. Delwail, D. Foster, J.C. Lecron, and H. Yssel. 2004. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. *J. Immunol.* 172:5154–5157.

21. Kuchen, S., R. Robbins, G.P. Sims, C. Sheng, T.M. Phillips, P.E. Lipsky, and R. Ettinger. 2007. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell–B cell collaboration. *J. Immunol.* 179:5886–5896.

22. Jacob, J., R. Kassir, and G. Kelsoe. 1991. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. *J. Exp. Med.* 173:1165–1175.

23. McHeyzer-Williams, M.G., M.J. McLean, P.A. Lalor, and G.J. Nossal. 1993. Antigen-driven B cell differentiation in vivo. *J. Exp. Med.* 178:295–307.

24. MacLennan, I.C., K.M. Toellner, A.F. Cunningham, K. Serre, D.M. Sze, E. Zuniga, M.C. Cook, and C.G. Vinuesa. 2003. Extrafollicular antibody responses. *Immunol. Rev.* 194:8–18.

25. Goodnow, C.C., J. Crosbie, S. Adelstein, T.B. Lavoie, S.J. Smith-Gill, R.A. Brink, H. Pritchard-Briscoe, J.S. Wotherspoon, R.H. Loblay, K. Raphael, et al. 1988. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. *Nature*. 334:676–682.

26. Mandik-Nayak, L., A. Bui, H. Noorchashm, A. Eaton, and J. Erikson. 1997. Regulation of anti–double-stranded DNA B cells in nonautoimmune mice: localization to the T–B interface of the splenic follicle. *J. Exp. Med.* 186:1257–1267.

27. Cyster, J.G., and C.C. Goodnow. 1995. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. *Immunity*. 3:691–701.

28. Mandik-Nayak, L., S.J. Seo, C. Sokol, K.M. Potts, A. Bui, and J. Erikson. 1999. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti–double-stranded DNA B cells. *J. Exp. Med.* 189:1799–1814.

29. Jacobson, B.A., D.J. Panka, K.A. Nguyen, J. Erikson, A.K. Abbas, and A. Marshak-Rothstein. 1995. Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice. *Immunity*. 3:509–519.

30. William, J., C. Euler, S. Christensen, and M.J. Shlomchik. 2002. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. *Science*. 297:2066–2070.

31. William, J., C. Euler, E. Leadbetter, A. Marshak-Rothstein, and M.J. Shlomchik. 2005. Visualizing the onset and evolution of an autoantibody response in systemic autoimmunity. *J. Immunol.* 174:6872–6878.

32. Luzina, I.G., S.P. Atamas, C.E. Storrer, L.C. daSilva, G. Kelsoe, J.C. Papadimitriou, and B.S. Handwerger. 2001. Spontaneous formation of germinal centers in autoimmune mice. *J. Leukoc. Biol.* 70:578–584.

33. Vinuesa, C.G., M.C. Cook, C. Angelucci, V. Athanasopoulos, L. Rui, K.M. Hill, D. Yu, H. Domaschenz, B. Whittle, T. Lambe, et al. 2005. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. *Nature*. 435:452–458.

34. Merino, R., M. Iwamoto, L. Fossati, and S. Izui. 1993. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB × NZW)F1 and MRL/MpJ-lpr/lpr mice. *J. Immunol.* 151:6509–6516.

35. Peng, S.L., M.P. Madaio, D.P. Hughes, I.N. Crispe, M.J. Owen, L. Wen, A.C. Hayday, and J. Craft. 1996. Murine lupus in the absence of alpha beta T cells. *J. Immunol.* 156:4041–4049.

36. Lentz, V.M., and T. Manser. 2001. Cutting edge: germinal centers can be induced in the absence of T cells. *J. Immunol.* 167:15–20.

37. Herber, D., T.P. Brown, S. Liang, D.A. Young, M. Collins, and K. Dunussi-Joannopoulos. 2007. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. *J. Immunol.* 178:3822–3830.

38. Dong, C., U.A. Temann, and R.A. Flavell. 2001. Cutting edge: critical role of inducible costimulator in germinal center reactions. *J. Immunol.* 166:3659–3662.

39. Tafuri, A., A. Shahinian, F. Bladt, S.K. Yoshinaga, M. Jordana, A. Wakeham, L.M. Boucher, D. Bouchard, V.S. Chan, G. Duncan, et al. 2001. ICOS is essential for effective T-helper-cell responses. *Nature*. 409:105–109.

40. Akiba, H., K. Takeda, Y. Kojima, Y. Usui, N. Harada, T. Yamazaki, J. Ma, K. Tezuka, H. Yagita, and K. Okumura. 2005. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. *J. Immunol.* 175:2340–2348.

41. Vogelzang, A., H.M. McGuire, D. Yu, J. Sprent, C.R. Mackay, and C. King. 2008. A fundamental role for interleukin-21 in the generation of T follicular helper cells. *Immunity*. 29:127–137.

42. McAdam, A.J., R.J. Greenwald, M.A. Levin, T. Chernova, N. Malenkovich, V. Ling, G.J. Freeman, and A.H. Sharpe. 2001. ICOS is critical for CD40-mediated antibody class switching. *Nature*. 409:102–105.

43. William, J., C. Euler, and M.J. Shlomchik. 2005. Short-lived plasma blasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. *J. Immunol.* 174:6879–6887.

44. Leonard, W.J., and R. Spolski. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. *Nat. Rev. Immunol.* 5:688–698.

45. Ansel, K.M., L.J. McHeyzer-Williams, V.N. Ngo, M.G. McHeyzer-Williams, and J.G. Cyster. 1999. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. *J. Exp. Med.* 190:1123–1134.

46. Campbell, D.J., C.H. Kim, and E.C. Butcher. 2001. Separable effector T cell populations specialized for B cell help or tissue inflammation. *Nat. Immunol.* 2:876–881.

47. Estes, J.D., T.C. Thacker, D.L. Hampton, S.A. Kell, B.F. Keele, E.A. Palenske, K.M. Druey, and G.F. Burton. 2004. Follicular dendritic cell regulation of CXCR4-mediated germinal center CD4 T cell migration. *J. Immunol.* 173:6169–6178.

48. Allen, C.D., K.M. Ansel, C. Low, R. Lesley, H. Tamamura, N. Fujii, and J.G. Cyster. 2004. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. *Nat. Immunol.* 5:943–952.

49. Hardtke, S., L. Ohl, and R. Forster. 2005. Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help. *Blood*. 106:1924–1931.

50. Veerman, K.M., M.J. Williams, K. Uchimura, M.S. Singer, J.S. Merzaban, S. Naus, D.A. Carlow, P. Owen, J. Rivera-Nieves, S.D. Rosen, and H.J. Ziltener. 2007. Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs. *Nat. Immunol.* 8:532–539.

51. Hauser, A.E., G.F. Debes, S. Arce, G. Cassese, A. Hamann, A. Radbruch, and R.A. Manz. 2002. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. *J. Immunol.* 169:1277–1282.

52. Wehrli, N., D.F. Legler, D. Finke, K.M. Toellner, P. Loetscher, M. Baggiolini, I.C. MacLennan, and H. Acha-Orbea. 2001. Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. *Eur. J. Immunol.* 31:609–616.

53. Ermak, T.H., H.J. Steger, and D. Wofsy. 1989. Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node. *Lab. Invest.* 61:447–456.

54. Hoyer, B.F., K. Moser, A.E. Hauser, A. Peddinghaus, C. Voigt, D. Eilat, A. Radbruch, F. Hiepe, and R.A. Manz. 2004. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. *J. Exp. Med.* 199:1577–1584.

55. Drayton, D.L., X. Ying, J. Lee, W. Lesslauer, and N.H. Ruddle. 2003. Ectopic LT $\alpha$  $\beta$  directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. *J. Exp. Med.* 197:1153–1163.

56. Picarella, D.E., A. Kratz, C.B. Li, N.H. Ruddle, and R.A. Flavell. 1992. Insulitis in transgenic mice expressing tumor necrosis factor

beta (lymphotoxin) in the pancreas. *Proc. Natl. Acad. Sci. USA.* 89: 10036–10040.

57. Ley, K., and G.S. Kansas. 2004. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. *Nat. Rev. Immunol.* 4:325–335.
58. Mohrs, K., A.E. Wakil, N. Killeen, R.M. Locksley, and M. Mohrs. 2005. A two-step process for cytokine production revealed by IL-4 dual-reporter mice. *Immunity.* 23:419–429.
59. Paus, D., T.G. Phan, T.D. Chan, S. Gardam, A. Basten, and R. Brink. 2006. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. *J. Exp. Med.* 203:1081–1091.
60. Dent, A.L., A.L. Shaffer, X. Yu, D. Allman, and L.M. Staudt. 1997. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. *Science.* 276:589–592.
61. Dong, C., A.E. Juedes, U.A. Temann, S. Shresta, J.P. Allison, N.H. Ruddle, and R.A. Flavell. 2001. ICOS co-stimulatory receptor is essential for T-cell activation and function. *Nature.* 409:97–101.
62. Vidal, S., D.H. Kono, and A.N. Theofilopoulos. 1998. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Fas lpr mice. *J. Clin. Invest.* 101:696–702.
63. Kong, P.L., T. Zhu, M.P. Madaio, and J. Craft. 2003. Role of the H-2 haplotype in Fas-intact lupus-prone MRL mice: association with autoantibodies but not renal disease. *Arthritis Rheum.* 48:2992–2995.